Asoprisnil
![]() | |
| Clinical data | |
|---|---|
| ATC code | none |
| Identifiers | |
| |
| CAS Number |
199396-76-4 |
| PubChem (CID) | 9577221 |
| IUPHAR/BPS | 2883 |
| ChemSpider |
7851660 |
| UNII |
72W09924WP |
| KEGG |
D02996 |
| ChEMBL |
CHEMBL267431 |
| Chemical and physical data | |
| Formula | C28H35NO4 |
| Molar mass | 449.582 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| | |
Asoprisnil (J867) is an investigational selective progesterone-receptor modulator developed by Schering and TAP Pharmaceutical Products, tested for treatment of progesterone-sensitive myomata.[1]
In 2005, phase-III trials were discontinued due to endometrial changes in patients. Whether asoprisnil will be marketed is uncertain.[2]
References
- ↑ DeManno D, Elger W, Garg R, et al. (2003). "Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy". Steroids. 68 (10-13): 1019–32. doi:10.1016/j.steroids.2003.09.008. PMID 14667995.
- ↑ Schering Interim Report Q1-3 2005
This article is issued from Wikipedia - version of the 5/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
